

## Subject index of volume 119

"Atypical" neuroleptics 231  
ABT-418 368  
Accidents 39  
Acetylcholine 139  
Acetylcholinesterase 391  
Acoustic startle response 71  
Adaptation 325  
Adenosine antagonists 99  
Aggression 353  
Aging 391  
Agonist 399  
Akathisia 1  
Alcohol 186, 205, 261  
Alcoholism 261  
1-allyl-3,7-dimethyl-8-p-sulfoxanthine 99  
Amitriptyline 277  
Amphetamine 79, 155  
Anandamine 282  
Antagonist correlation analysis 222  
Antidepressants 15, 47, 440  
Antinociception 282  
Antipsychotic agents 133  
d-AP5 55  
Apomorphine 79, 414  
L-Arginine 115  
Arousal 39  
Attention 66, 139, 315  
Atypical neuroleptics 428  
Auditory evoked potentials 163  
Autoreceptor 299  
Behaviour 20  
Benzodiazepine 105, 399  
Benzodiazepines 27, 39  
Buprenorphine 268  
Buspirone 47  
Caffeine 66, 99  
Cannabidiol 282  
Carbon monoxide 193  
Cardiovascular effects 205  
Cat 20  
Catalepsy 282  
Chlormethiazole 247  
Cholinergic system 305  
Cigarette smoking 349  
Classical conditioning 414  
Clozapine 291  
Cluster analysis 361  
Cocaine 79, 92, 179  
Cocaine analogs 376  
Cocaine base 127  
Cognition 295  
Cognitive function 325  
Combination treatment 342  
Conditioned place preference 92  
Conditioned taste aversion 213  
Consolidation 155  
Cortisol 311  
CP-55,940 282  
d-CPP 55  
Crack 127  
Craving 171  
8-cyclopentyl-1,3-dipropylxanthine 99  
CYP2D6 genotype and phenotype 345  
D<sub>1</sub> receptors 79  
D<sub>1</sub>-dopamine receptors 1  
D<sub>2</sub> dopamine receptors 345  
Delayed response 391  
Dependence 268  
Depression 277, 342, 449  
Desipramine 15, 47  
5,7-DHT (5,7-dihydroxytryptamine) 9  
Diazepam 9, 399, 421  
Dihydrexidine 79  
2,5-Dimethoxy-4-methylamphetamine (DOM) 239  
DOI 291  
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) 9  
Dopamine 15, 71, 145, 299  
Dopamine D<sub>1</sub> and D<sub>2</sub> receptors 34  
Dopamine D<sub>1</sub> receptor 466  
Dopamine receptors 145  
Dopamine transporter 376  
Dose-response 79  
Double-blind method 39  
Drug discrimination 79  
Drug discrimination 368  
Drug selfadministration 127  
Drug-induced stimulus control 222  
Drug-induced stimulus control (DISC) 239  
d-Tubocurarine 163  
Ecstasy 247  
EEG 349, 361  
Elderly patients 277  
Electric shock 261  
Electroconvulsive shock 99  
Electroconvulsive therapy 440  
Endogenous opioid systems 92  
Endozepines 295  
Epilepsy 115  
Ethanol 353, 455  
Ethanol self-administration 186  
Event-related potentials 455  
Excitatory amino acid 55  
Explicit memory 27  
Factor analysis 361  
Familial-genetic risk 261  
Fenfluramine 311  
FG-8205 399  
Fixed ratio 127  
Flumazenil 295  
Fluoxetine 15  
Food deprivation 127  
Food satiation 127  
Footshock 334  
Forced swim test 47  
Free recall 155  
GABA 20, 105  
Gender differences 205  
Globus pallidus 20  
Glutamate 20  
Glycine 55  
Grooming 145  
(R)-HA-966 55  
Haloperidol 34, 124, 213  
Head shake 9  
Heroin 334  
Hippocampus 282  
5-HT 47  
5-HT<sub>1A</sub> agonists 47  
5-HT<sub>1A</sub> receptors 311  
5-HT<sub>2</sub> receptors 345  
5-HT<sub>2A</sub> 9, 222  
5-HT<sub>2C</sub> 222  
5-HT<sub>2C</sub> receptor 466  
5-HT<sub>3</sub> antagonist 186  
5-HT<sub>3</sub> receptor antagonists 213  
5-HT<sub>4</sub> 186  
Human 105, 345, 353  
Human memory 155  
Humans 305, 405, 455  
Hunger reduction 414  
6-Hydroxydopamine 145, 466  
5-Hydroxytryptamine 247  
Hyperthermia 247  
Hypoglycemia 325  
ICI 204 636 231  
Immobilization stress 9  
In vivo microdialysis 334  
Individual variation 361  
Information processing 455  
Intravenous drug self-administration 334  
[<sup>3</sup>H]Ketanserin binding 9  
Kindling 115  
Latent inhibition 414  
Liver 295  
Locomotion 145, 299  
Locomotor activity 213, 428  
Locus of control 449  
Lorazepam 105, 315  
LTP 115  
Lysergic acid diethylamide (LSD) 239  
Male rat sexual behaviour 291  
Males 261  
Man 311  
*m*-Chlorophenylpiperazine 466  
*m*-Chlorophenylpiperazine (mCPP) 222  
MDMA 247  
Mecamylamine 213, 368  
Memory 66, 315, 391, 405  
Mesocorticolimbic DA system 71  
Methadone 268  
Methamphetamine 34  
3,4-Methylenedioxymethamphetamine 247  
Microdialysis 15  
Mitochondrial impairment 474  
Monoamine oxidase inhibitors 342  
Mood 66  
Morphine 186  
Mouse ambulation 34  
Mouse striatum 376  
Muscarinic 139  
N. accumbens 428  
Naloxone 92  
Naltrexone 334  
L-NAME 115  
Nausea 1  
Neostriatum 145  
Neuroglycopenia 325  
Neuroleptics 247  
Neuropsychology 295  
Neurotoxicity 247  
Nicotine 124, 205, 213, 305, 368, 385, 405

## Subject index of volume 119

"Atypical" neuroleptics 231  
ABT-418 368  
Accidents 39  
Acetylcholine 139  
Acetylcholinesterase 391  
Acoustic startle response 71  
Adaptation 325  
Adenosine antagonists 99  
Aggression 353  
Aging 391  
Agonist 399  
Akathisia 1  
Alcohol 186, 205, 261  
Alcoholism 261  
1-allyl-3,7-dimethyl-8-p-sulfoxanthine 99  
Amitriptyline 277  
Amphetamine 79, 155  
Anandamine 282  
Antagonist correlation analysis 222  
Antidepressants 15, 47, 440  
Antinociception 282  
Antipsychotic agents 133  
d-AP5 55  
Apomorphine 79, 414  
L-Arginine 115  
Arousal 39  
Attention 66, 139, 315  
Atypical neuroleptics 428  
Auditory evoked potentials 163  
Autoreceptor 299  
Behaviour 20  
Benzodiazepine 105, 399  
Benzodiazepines 27, 39  
Buprenorphine 268  
Buspirone 47  
Caffeine 66, 99  
Cannabidiol 282  
Carbon monoxide 193  
Cardiovascular effects 205  
Cat 20  
Catalepsy 282  
Chlormethiazole 247  
Cholinergic system 305  
Cigarette smoking 349  
Classical conditioning 414  
Clozapine 291  
Cluster analysis 361  
Cocaine 79, 92, 179  
Cocaine analogs 376  
Cocaine base 127  
Cognition 295  
Cognitive function 325  
Combination treatment 342  
Conditioned place preference 92  
Conditioned taste aversion 213  
Consolidation 155  
Cortisol 311  
CP-55,940 282  
d-CPP 55  
Crack 127  
Craving 171  
8-cyclopentyl-1,3-dipropylxanthine 99  
CYP2D6 genotype and phenotype 345  
D<sub>1</sub> receptors 79  
D<sub>1</sub>-dopamine receptors 1  
D<sub>2</sub> dopamine receptors 345  
Delayed response 391  
Dependence 268  
Depression 277, 342, 449  
Desipramine 15, 47  
5,7-DHT (5,7-dihydroxytryptamine) 9  
Diazepam 9, 399, 421  
Dihydrexidine 79  
2,5-Dimethoxy-4-methylamphetamine (DOM) 239  
DOI 291  
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) 9  
Dopamine 15, 71, 145, 299  
Dopamine D<sub>1</sub> and D<sub>2</sub> receptors 34  
Dopamine D<sub>1</sub> receptor 466  
Dopamine receptors 145  
Dopamine transporter 376  
Dose-response 79  
Double-blind method 39  
Drug discrimination 79  
Drug discrimination 368  
Drug selfadministration 127  
Drug-induced stimulus control 222  
Drug-induced stimulus control (DISC) 239  
d-Tubocurarine 163  
Ecstasy 247  
EEG 349, 361  
Elderly patients 277  
Electric shock 261  
Electroconvulsive shock 99  
Electroconvulsive therapy 440  
Endogenous opioid systems 92  
Endozepines 295  
Epilepsy 115  
Ethanol 353, 455  
Ethanol self-administration 186  
Event-related potentials 455  
Excitatory amino acid 55  
Explicit memory 27  
Factor analysis 361  
Familial-genetic risk 261  
Fenfluramine 311  
FG-8205 399  
Fixed ratio 127  
Flumazenil 295  
Fluoxetine 15  
Food deprivation 127  
Food satiation 127  
Footshock 334  
Forced swim test 47  
Free recall 155  
GABA 20, 105  
Gender differences 205  
Globus pallidus 20  
Glutamate 20  
Glycine 55  
Grooming 145  
(R)-HA-966 55  
Haloperidol 34, 124, 213  
Head shake 9  
Heroin 334  
Hippocampus 282  
5-HT 47  
5-HT<sub>1A</sub> agonists 47  
5-HT<sub>1A</sub> receptors 311  
5-HT<sub>2</sub> receptors 345  
5-HT<sub>2A</sub> 9, 222  
5-HT<sub>2C</sub> 222  
5-HT<sub>2C</sub> receptor 466  
5-HT<sub>3</sub> antagonist 186  
5-HT<sub>3</sub> receptor antagonists 213  
5-HT<sub>4</sub> 186  
Human 105, 345, 353  
Human memory 155  
Humans 305, 405, 455  
Hunger reduction 414  
6-Hydroxydopamine 145, 466  
5-Hydroxytryptamine 247  
Hyperthermia 247  
Hypoglycemia 325  
ICI 204 636 231  
Immobilization stress 9  
In vivo microdialysis 334  
Individual variation 361  
Information processing 455  
Intravenous drug self-administration 334  
[<sup>3</sup>H]Ketanserin binding 9  
Kindling 115  
Latent inhibition 414  
Liver 295  
Locomotion 145, 299  
Locomotor activity 213, 428  
Locus of control 449  
Lorazepam 105, 315  
LTP 115  
Lysergic acid diethylamide (LSD) 239  
Male rat sexual behaviour 291  
Males 261  
Man 311  
*m*-Chlorophenylpiperazine 466  
*m*-Chlorophenylpiperazine (mCPP) 222  
MDMA 247  
Mecamylamine 213, 368  
Memory 66, 315, 391, 405  
Mesocorticolimbic DA system 71  
Methadone 268  
Methamphetamine 34  
3,4-Methylenedioxymethamphetamine 247  
Microdialysis 15  
Mitochondrial impairment 474  
Monoamine oxidase inhibitors 342  
Mood 66  
Morphine 186  
Mouse ambulation 34  
Mouse striatum 376  
Muscarinic 139  
N. accumbens 428  
Naloxone 92  
Naltrexone 334  
L-NAME 115  
Nausea 1  
Neostriatum 145  
Neuroglycopenia 325  
Neuroleptics 247  
Neuropsychology 295  
Neurotoxicity 247  
Nicotine 124, 205, 213, 305, 368, 385, 405

Nicotine dependence 171  
 Nicotine gum 193  
 Nicotinic 139  
 Nicotinic acetylcholine receptors 368  
 Nitric oxide 115  
 L-Nitro-arginine 115  
 3-Nitropionic acid 474  
 NNC 756 1  
 Non-human primates 391  
 Nonlinearity 349  
 8-OH-DPAT 47  
 Olanzapine 133  
 Olfactory tubercle 428  
 Onset of action 440  
 Opiate 186  
 Opioid 268  
 Opioid drugs 334  
 Oral activity 466  
 Oro-facial dyskinesia 20  
 P300 455  
 Pain 261  
 Parkinsonism 55  
 Parkinson's disease 145  
 Paroxetine 277  
 Partial agonist 399  
 Paw test 428  
 Pecking 414  
 Perceptual speed 305  
 Pharmaco-EEG 231  
 Phenylpropanolamine 85  
 Pigeons 414  
 Pindolol 311  
 Placebo effect 449  
 Positron emission tomography 1, 345  
 Post-methamphetamine treatment 34  
 Prefrontal cortex 15  
 Prefrontal neocortex 139  
 Prepulse inhibition 71  
 Problem solving 66  
 Progressive ratio 127  
 Prolactin 231, 311  
 Psychomotor speed 295  
 Psychomotor tests 39  
 Punished responding 133  
 Quinpirole 299  
 Radial-arm maze 282  
 Rat 71, 139, 299, 399  
 Rating scales 449  
 Rats 79, 99, 186, 474  
 Reaction time 295  
 Receptors 139  
 Rectal temperature 282  
 Reflective processes 27  
 Refractory depression 342  
 Reinforcement 193  
 Reinforcement mechanism 414  
 Reinforcing efficacy 127  
 Reinstatement 334  
 Relapse 334  
 Repeated administration 34  
 Rhesus monkey 421  
 Rhesus monkeys 127  
 Risperidone pharmacokinetics 345  
 SCH 23390 1, 34, 79  
 Schizophrenia 71, 124, 163, 231  
 Scopolamine 315  
 Sedation 27  
 Seizures 99, 115  
 Selective serotonin reuptake inhibitors 277  
 Self-administration 385  
 Sensitization 34, 414  
 Sensory gating 163  
 Serial probe recognition task 421  
 Serquel 231  
 Serotonin 15, 71, 179, 353  
 Serotonin (5-HT) 222  
 Serotonin receptors 291  
 Serotonin selective reuptake inhibitors 342  
 Side effects 39  
 SKF 38393 79, 466  
 Smokers 205  
 Smoking 85, 124, 127, 361, 385  
 Smoking cessation 171  
 Smoking self-report 193  
 State-dependency 399  
 Stress 334  
 Striatum 466  
 Subjective effects 205  
 Subjective responses 385  
 Substantia nigra 145  
 Subthalamic nucleus 20  
 Sulpiride 299  
 Supersensitivity 466  
 Symptoms of hypoglycemia 325  
 Tardive dyskinesia 474  
 $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC) 282  
 Thigmotactic scanning 145  
 Time course 440  
 Tolerance 385, 414  
 Topography 361  
 Treatment of depression 342  
 Triazolam 27  
 Tropisetron 186  
 Tryptophan 179, 353  
 Tryptophan depletion 353  
 Turning 145  
 Type 1 diabetes 325  
 Urges 171  
 Vacuous chewing movements 474  
 Ventral tegmental area 368  
 Vigilance 315  
 Vigilance performance 39  
 Visual perception 105  
 Weight 85  
 WIN-55,212-2 282  
 Withdrawal 268, 334  
 Working memory 139  
 Zolpidem 399